Factor XIII deficiency (FXIIID) is a rare hereditary bleeding disorder arising from heterogeneous mutations, which can lead to life-threatening hemorrhage. The diagnosis of FXIIID is challenging due to normal standard coagulation assays requiring specific FXIII assays for diagnosis, which is especially difficult in developing countries. This report presents an overview of FXIIID diagnosis and laboratory methods and suggests an algorithm to improve diagnostic efficiency and prevent missed or delayed FXIIID diagnosis. Assays measuring FXIII activity: The currently available assays utilized to diagnose FXIIID, including an overview of their complexity, reliability, sensitivity, and specificity, as well as mutational analysis are reviewed. The use of a FXIII inhibitor assay is described. Diagnostic tools in FXIIID: Many laboratories are not equipped with quantitative FXIII activity assays, and if available, limitations in lower activity ranges are important to consider. Clot solubility tests are not standardized, have a low sensitivity, and are therefore not recommended as routine screening test; however, they are the first screening test in almost all coagulation laboratories in developing countries. To minimize the number of patients with undiagnosed FXIIID, test quality should be improved in less well-equipped laboratories. Common country-specific mutations may facilitate diagnosis through targeted genetic analysis in reference laboratories in suspected cases. However, genetic analysis may not be feasible in every country and may miss spontaneous mutations. Centralized FXIII activity measurements should also be considered. An algorithm for diagnosis of FXIIID including different approaches dependent upon laboratory capability is proposed.
| INTRODUCTION
Inherited factor XIII deficiency (FXIIID) is a rare bleeding disorder affecting the final stage of the coagulation system and resulting in a bleeding diathesis. 1 The worldwide incidence of FXIIID, inherited as an autosomal recessive disorder, is approximately one per 1-3 million people. Its prevalence depends on geographic region and is higher in areas in which consanguineous marriage is common; however, there is no difference worldwide in affected ethnicity or race. The molecular defects in FXIIID arise from heterogeneous mutations, which can be country-specific, facilitating methods to confirm FXIIID diagnosis in such areas. [2] [3] [4] Signs and symptoms of FXIIID range from life-threatening hemorrhage such as intracranial hemorrhage to mild forms, including skin bleeding. Umbilical cord bleeding and soft tissue hematoma are the most common and often the first symptom of FXIIID. 3, 5, 6 In women with severe FXIIID, recurrent miscarriage is common. Heterozygous carriers may show a bleeding tendency upon provocation such as traumatic injury or invasive procedures, and in some cases, umbilical cord bleeding, menorrhagia, miscarriages, or postpartum bleeding. [7] [8] [9] The diagnosis of FXIIID is challenging due to the rarity of the disorder and because standard coagulation screening tests, including prothrombin time, activated partial thromboplastin time, thrombin time, platelet count, or bleeding time, are normal; therefore, specific FXIII assays are required. FXIIID remains one of the most underdiagnosed rare bleeding disorders. [10] [11] [12] Although comprehensive guidelines for
FXIIID diagnosis have been published by the International Society on Thrombosis and Haemostasis Scientific and Standardization
Committee (ISTH-SSC), these have not been implemented uniformly worldwide due to insufficient laboratory assay resources. 13 However, they have lead to a significant improvement in diagnostic efficiency in parts of the world in which they are used for diagnosis. Therefore, novel approaches are required for the diagnosis of FXIIID to address the gap between expected prevalence and established diagnoses.
A report on the Annual Global Survey of the worldwide distribution of rare bleeding disorders by the World Federation of Hemophilia published in October 2015 revealed 1327 patients with FXIIID registered from 65 counties. 14 This survey revealed that half of available data originated from Europe, underscoring the need for increased efforts to establish accurate diagnosis and improve worldwide data collection systems. Based upon this survey, many developing countries did not report patients with FXIIID, emphasizing the difficulty in diagnosis in resource-poor settings. The data further underscore the need to improve diagnostic tools and develop novel approaches to diagnose patients with FXIIID.
The aim of this report was to present a comprehensive and updated overview of FXIIID diagnosis, including diagnostic tools and challenges, and to propose an algorithm that may be considered to improve diagnostic efficiency and prevent missed or delayed FXIIID diagnosis, thereby reducing morbidity and mortality of patients with this disease.
| RESULTS

| Assays used to measure FXIII activity
Assays to measure FXIII activity are based on the transglutaminase reaction catalyzed by FXIII after its activation, which is described below.
| Factor XIII activation process
FXIII is a proenzyme, protransglutaminase, which circulates in an inactive form as a heterotetramer consisting of two catalytic A subunits and two carrier/protective B subunits (FXIII-A 2 B 2 ). 13 FXIII is activated in three steps: initially, the activation peptide A, consisting of 37 amino acids, is cleaved from subunit A in the presence of fibrin and thrombin. Subsequently, subunit B is dissociated from subunit A in the presence of calcium and fibrin. Lastly, in the presence of calcium, the cleaved FXIII-A 2 undergoes conformational changes exposing activesite cysteine residues, which react with fibrin monomers catalyzing their cross-linking.
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| Transglutaminase reaction catalyzed by activated FXIII
Activated FXIII (FXIIIa) acts in the final stage of coagulation to stabilize the fibrin clot. In a first step, the cysteine residue of activated subunit A reacts with a glutamine residue of a gamma chain fibrin molecule, forming a binary complex, a process during which ammonia is released ( Figure 1A) . In a second step, this binary complex can undergo two different subsequent reactions: (i) the primary amine group of a lysine residue from another gamma chain fibrin molecule breaks the binary complex thioester bond in a transglutaminase reaction and reacts with the glutamine residue, forming a glutaminyl-lysyl bond ( Figure 1B) ; (ii) a free amine group reacts with the binary complex, resulting in an isopeptide glutamine-amine bond ( Figure 1C ). These reactions, including ammonia release, transglutaminase reaction, and incorporation of a free amine group into the glutamine-FXIIIa complex, result in gamma chain fibrin to fibrin dimerization and cross-linking, and form the fundamental basis for laboratory assays measuring FXIII activity via specific products released during these steps. 16 In addition to cross-linking gamma chain fibrin molecules, acti- 
| Clot solubility test (CST)
The first case of FXIIID described was diagnosed in 1960 using this method. 19 Its sensitivity to FXIII activity levels depends on fibrinogen 
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Hypofibrinogenemia and dysfibrinogenemia can be confirmed or excluded using thrombin time, reptilase time, and/or a fibrinogen antigen assay in conjunction with a fibrinogen activity assay. High pepsinogen levels, as they may occur in patients with gastric diseases or a helicobacter pylori infection, can also lead to a false-positive CST when using acetic acid-based assays.
20
The advantages of the CST are that it is easy to perform, inexpensive, and without specific instrumentation requirements, so that it can be established in most laboratories. However, disadvantages include a lack of standardization and low sensitivity (inability to detect mild or moderate deficiency, including heterozygous carriers).
The CST therefore underestimates the number of FXIIID cases, may lead to missed or delayed diagnosis, and cannot be used for monitoring prophylactic treatment. 4, 10, 13 Although it is not recommended as a routine screening test for the aforementioned reasons, the CST is often the first screening test utilized in many coagulation laboratories in developing countries as well as in 20% of developed countries.
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Apart from resource issues, the lack of regulatory approval for some commercially available quantitative assays may present a barrier to more widespread adoption and use. Therefore, these assays cannot be 
Ammonia release assay
Amine incorporaƟon assay
Photometric or fluorogenic transglutaminase acƟvity assays
Clotting agent
Solubilizing agent
Sensitivity to FXIII levels (%) Comment
| Quantitative assays (functional activity assays)
Quantitative FXIII activity assays are recommended as first-line screening tests whenever possible. Three main methods are used to measure FXIII activity levels, all currently based upon the transglutaminase reaction in the cross-linking process: (i) ammonia release assay, (ii) amine incorporation assay, and (iii) isopeptidase assay. 13, 16 There are challenges and limitations to each of the quantitative methods used for FXIIID diagnosis, the major disadvantages being variation in the limit of quantitation (<1%-10%) and low sensitivity. The details of these three methods, including advantages and disadvantages, are described below and in Table 2 .
2,10,13,16,21,22
• The ammonia release assay is the most common and convenient method due to the short time required for performance (10 minutes • In the amine incorporation assay, fluorescent, radiolabeled, or biotinylated amines covalently bound to a glutamine residue of a substrate are measured after free unbound amines have been separated from the protein-bound fraction. Although amine incorporation assays are more sensitive than the ammonia release assay, they are more difficult to standardize, have difficulty with reproducibility, and are time-consuming. Moreover, certain types of this assay that measure transglutaminase activity at the initial stage of FXIII activity are sensitive to the Val34Leu FXIII polymorphism, resulting in falsely increased FXIII activity when present, whereas those assays measuring the transglutaminase activity of the completely activated enzyme are not affected.
13
• The isopeptidase assay is based on the isopeptidase activity of FXIIIa under certain conditions, which results in the gradual removal of primary amines bound to a glutamine residue in an oligopeptide.
This gradual release of amines containing a quencher results in increased fluorescence of a peptide substrate, which is labeled with a fluorophore. 16 Although overestimation does not occur in this assay, the limit of quantitation is around 5% normal FXIII activity; therefore, it is less sensitive than other FXIII activity assays. The FXIII antigen ELISA method has a limit of detection of 0.014 μg/L (FXIII-A), 0.019 μg/L (FXIII-B), and 0.016 μg/L (FXIII-A 2 B 2 ), laboratory imprecision of <12%, and an estimated total error of <25%. 24 The R-ELISA FXIII method is a one-step sandwich ELISA with good sensitivity (as low as 0.1%) and suitable for monitoring substitution therapy. 16, 24 Other methods, including EIA and RIA, are used infrequently due to lower sensitivity, laborious procedures, or because they may produce artifacts. 
| Inhibitor (autoantibody) assays
Detected low factor activity can be attributed to congenital factor deficiency or development of an autoantibody, leading to autoimmune T A B L E 2 Different methods to measure FXIII activity • Slight modification of assay can decrease its detection limit to <1%
• 
| FXIII molecular (genetic) analysis
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Severe and spontaneous bleeding episodes occur in both homozygous and heterozygous patients, the latter more commonly under hemostatic stress situations. [7] [8] [9] FXIII subunit B deficiency accounts for less than 5% of recognized FXIIID cases. The B subunit gene is located on chromosome 1 and contains 12 exons and 11 introns; 16 mutations, mostly missense, have been reported. 28 The absence of FXIII subunit B leads to shorter plasma half-life of FXIII subunit A. FXIII subunit B deficiency causes a less severe phenotype due to the remaining 5%-10% FXIII activity present in the plasma.
6,27
The FXIII-A gene is highly polymorphic, and a number of molecular variants have been characterized. FXIII-specific activity in normal individuals is related to specific polymorphisms in the FXIII-A gene. More than 1000 noncoding polymorphisms have been observed in both FXIII subunits. Five common coding polymorphisms have been detected in the FXIII-A gene and affect either FXIII activity or plasma level:
Val34Leu (the most common; accelerated FXIII activation), Tyr204Phe
(decreased FXIII plasma level and activity), Pro564Leu (decreased FXIII plasma level and increased FXIII activity), Glu651Gln, and Val650IIe
(low to normal FXIII activity). 27 The frequency of polymorphisms has been observed to be dependent on ethnicity. The spectrum of common FXIII-A gene mutations in a few selected countries, including both developed and developing countries, is shown in Table 4 . 27 In some countries, molecular analysis can facilitate diagnosis if populationspecific mutations are known. Based on this knowledge, genetic analysis in some countries may aid diagnosis, especially in less wellequipped coagulation laboratories; in this circumstance, after a CST, targeted genetic analysis could be performed in reference laboratories prior to more specific FXIII activity and antigen assays. This strategy involves a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay or the sequencing of a short specific DNA segment limited to one or two exons, both of which require knowledge of specific primers; this type of testing requires less than 24 hours.
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This strategy may be useful in countries in which highly specific recurrent mutations are common; it will not detect spontaneous novel
mutations. An example where this strategy has been employed is Iran, where nearly one-third of all patients with FXIIID worldwide have been reported. Two mutations are found commonly, of which one (c.562T>C) was detected in 95% of affected patients. 29, 30 with these founder mutations has allowed for genetic counseling of relatives of affected patients, many of whom are likely to be heterozygous carriers, with an option for antenatal diagnosis. In geographic regions with a known elevated incidence of FXIIID, and particularly among families with affected homozygous FXIIID individuals, the targeted diagnosis and appropriate management of heterozygous carriers may be prudent in the context of premarital or family planning counseling, planned invasive procedures, bleeding symptoms, miscarriage, or menorrhagia.
| DISCUSSION
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The establishment of a national reference laboratory for analysis is ideal in countries with less well-equipped local coagulation laboratories. Countries with a wide variety of causative mutations do not lend themselves to use of targeted genetic analysis, and hence confirmation of FXIIID through specific FXIII activity assays in a central, national, or international laboratory is required. Access to a reference laboratory that can perform FXIII activity assays is crucial for the diagnosis of symptomatic milder FXIIID and heterozygous carriers, who cannot be identified using CSTs alone. In such areas, the CST quality should also be optimized through use of two simultaneous different CST methods.
Therefore, an algorithm for diagnosis of FXIIID reflecting a variety of approaches based upon local coagulation laboratory availability and capability for FXIII assays is proposed (Figure 2 ).
The first step in the diagnostic approach to FXIIID requires detailed patient and family history, and a clinical evaluation, with attention to bleeding episodes typical of the disorder. In suspected cases, the proposed algorithm may be utilized. There exist limitations to existing quantitative FXIII activity assays, including the most commonly utilized ammonia release assay, even in well-equipped laboratories, most specifically in the low activity ranges; the use of a plasma blank minimizes this effect and allows differentiation of severe cases. Less well-equipped laboratories, without the capacity to perform quantitative assays, may use CST in conjunction with country-specific centralized targeted mutation analysis or FXIII activity measurement to ensure timely diagnosis. Using this combination of approaches may result in improved diagnostic capacity and case identification.
